Lucatumumab Biosimilar - Research Grade

Human

CD40

>1mg/ml

Human IgG1 (S131A)-Kappa

Anti-Mouse CD40 (FGK4.5) In Vivo Antibody - Low Endotoxin (ICH1073), Bulk Anti-Human CD40 (G28.5) Antibody (ICH1156), Dacetuzumab Biosimilar - Research Grade (ICH5030), Sotigalimab Biosimilar - Research Grade (ICH5031), Selicrelumab Biosimilar - Research Grade (ICH5032), Abiprubart Biosimilar - Research Grade (ICH5323), Bleselumab Biosimilar - Research Grade (ICH5407), Cifurtilimab Biosimilar - Research Grade (ICH5437), Dalnicastobart Biosimilar - Research Grade (ICH5462), Giloralimab Biosimilar - Research Grade (ICH5571), Iscalimab Biosimilar - Research Grade (ICH5610), Mitazalimab Biosimilar - Research Grade (ICH5689), Ravagalimab Biosimilar - Research Grade (ICH5806), Teneliximab Biosimilar - Research Grade (ICH5915)

https://www.imgt.org/mAb-DB/

ICH3002

P25942

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of lucatumumab, a fully human anti-CD40 antagonist antibody, supplied for research use only. It is built around the human CD40 target and formatted as a human IgG1(kappa) with an S131A framework substitution, providing a reproducible tool for interrogating CD40-CD40L (CD154) signaling in vitro and in preclinical models. Typical research applications include use as a binding and blocking reference standard, a positive control in CD40-directed assay development, a benchmarking reagent for comparing new anti-CD40 candidates, and a building block for ADCC or antibody-drug-conjugate feasibility work. It is not the clinical drug and is not intended for human or veterinary use. Material is offered at research-grade low endotoxin (<1 EU/mg), with an ultra-low-endotoxin option (<0.5 EU/mg) suitable for endotoxin-sensitive cell and in-vivo standard workflows, and is available in bulk milligram-to-gram quantities to support scale-up, screening campaigns, and longitudinal studies requiring lot consistency. CD40 (TNFRSF5; UniProt P25942) is a type I transmembrane costimulatory receptor of the TNF receptor superfamily, expressed on B cells, dendritic cells, macrophages, and many non-hematopoietic and tumor cells. Its ligand, CD40L (CD154), is expressed largely on activated CD4+ T cells and platelets. CD40 engagement recruits TRAF adaptors and activates NF-kappaB, MAPK, and PI3K pathways, driving B-cell proliferation, immunoglobulin class-switch recombination, germinal center formation, and antigen-presenting-cell maturation with upregulated costimulatory molecules and cytokines. This axis is central to humoral immunity and T-cell priming. Aberrant CD40 signaling contributes to autoimmunity, inflammation, and the survival of CD40-expressing malignancies, making CD40 a target for both antagonist (signal-blocking) and agonist (immune-activating) antibody strategies.

CD40, Bp50, CDW40, TNFRSF5, p50, CD40 (protein), CD40 molecule

Detects human CD40

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.